Ann: Media release - First stroke patient with afamelanotide, page-17

You pretty much spend all your time commenting on 2 companies which you don't own and have sentiment 'Sell'. Now you have made a couple of comments on a successful Biotech in Clinuvel about which you know practically nothing and also don't hold so are you a shorter or acting for a shorter?

I challenge you to find a Biotech on the ASX which represents better value than CUV. If it is there I have missed it. Clinuvel has largely derisked with FDA, EMA, TGA, Israel approvals. It is highly profitable, controls costs well, has no debt and is expanding into galactic indications with a drug already well known as extremely safe. Importantly it is undervalued compared to all those other biotechs which are for the most part losing money still and seeking approvals. Just come back here in only 2 months from now and see the end of year financial results for CUV and realise what you are missing out on. These results will IMO make CUV even more of a standout on valuation terms.

All IMO DYOR
DYOR particularly applies to you Pigs you have a lot to learn there are a LOT of other Biotechs on HotCopper who could use your scrutiny before CUV